Pharmacological interventions for binge eating: Lessons from animal models, current treatments, and future directions

Current Pharmaceutical Design

Volumn 17, Issue 12, 2011, Pages 1180-1187

  Berner, Laura A ^a   Bocarsly, Miriam E ^b   Hoebel, Bartley G ^b   Avena, Nicole M ^b,c  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b PRINCETON UNIVERSITY   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Binge eating; Cannabinoid; Dopamine; Gaba; Opioid; Preclinical models

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 4 AMINOBUTYRIC ACID; BACLOFEN; CANNABINOID; DOPAMINE; FLUOXETINE; NALTREXONE; NEUROTRANSMITTER; OPIATE; OPIATE ANTAGONIST; OPIATE RECEPTOR; RIMONABANT; TOPIRAMATE;

ALCOHOLISM; BINGE EATING DISORDER; DOPAMINERGIC ACTIVITY; DRUG EFFICACY; FOOD INTAKE; HUMAN; NEUROCHEMISTRY; NEUROIMAGING; NONHUMAN; PALATABILITY; PRIORITY JOURNAL; REVIEW; TASTE PREFERENCE;

EID: 79957639538     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211795656774     Document Type: Review

References (113)

1. Hudson JI, Hiripi E, Pope HG, Kessler RC. The prevalence andcorrelates of eating disorders in the National Comorbidity Surveyreplication. Biol Psychiatry 2007; 61(3): 348-58.
2. Keel PK, Brown TA. Update on course and outcome in eatingdisorders. Int J Eat Disord 2010; 43(3): 195-204.
3. Stunkard AJ. Eating patterns and obesity. Psychiatr Q 1959; 33:284-95.
4. Davis CA, Levitan RD, Reid C, et al. Dopamine for wanting andopioids for liking: a comparison of obese adults with and withoutbinge eating. Obesity (Silver Spring) 2009; 17(6): 1220-5.
5. American Psychiatric Association. Diagnostic and StatisticalManual of Mental Disorders: Fouth Edition, Text Revision (DSMIV-TR). Washington, DC: American Psychiatric Association; 2000.
6. Reas DL, Grilo CM. Review and meta-analysis ofpharmacotherapy for binge-eating disorder. Obesity 2008; 16(9):2024-38.
7. Bodell LP, Devlin MJ. Pharmacotherapy for binge-eating disorder.In: Grilo CM, Mitchell JE, editors. The Treatment of EatingDisorders: A Clinical Handbook. New York: Guilford Press; 2010;p. 402-13.
8. Bacaltchuk J, Hay P. Antidepressants versus placebo for peoplewith bulimia nervosa. Cochrane Database of System Rev 2003; (4):CD003391.
9. Shapiro JR, Berkman ND, Brownley KA, Sedway JA, Lohr KN, Bulik CM. Bulimia nervosa treatment: a systematic review ofrandomized controlled trials. Int J Eat Disord 2007; 40(4): 321-36.
10. Broft A, Berner LA, Walsh BT. Pharmacotherapy for bulimianervosa. In: Grilo CM, Mitchell JE, editors. The Treatment ofEating Disorders: A Clinical Handbook. New York: Guilford Press;2010. p. 388-401.
11. Leibowitz S, Alexander J. Hypothalamic serotonin in control ofeating behavior, meal size, and body weight. Biol Psychiatry 1998;44(9): 851-64.
12. Leibowitz S, Weiss G, Suh J. Medial hypothalamic nuclei mediateserotonin's inhibitory effect on feeding behavior. PharmacolBiochem Behav 1990; 37(4): 735-42.
13. Kaye W. Neurobiology of anorexia and bulimia nervosa. PhysiolBehav 2008; 94(1): 121-35.
14. Arnold LM, McElroy SL, Hudson JI, Welge JA, Bennett AJ, Keck PE. A placebo-controlled, randomized trial of fluoxetine in thetreatment of binge-eating disorder. J Clin Psychiatry 2002; 63:1028-33.
15. Grilo CM, Masheb RM, Wilson GT. Efficacy of cognitivebehavioral therapy and fluoxetine for the treatment of binge eatingdisorder: a randomized double-blind placebo-controlledcomparison. Biol Psychiatry 2005; 57(3): 301-9.
16. Bello NT, Hajnal A. Dopamine and binge eating behaviors. Pharmacol Biochem Behav 2010; 97: 25-33.
17. Rada P, Avena NM, Hoebel BG. Daily bingeing on sugarrepeatedly releases dopamine in the accumbens shell. Neuroscience 2005; 134(3): 737-44.
18. Avena NM, Rada P, Moise N, Hoebel BG. Sucrose sham feedingon a binge schedule releases accumbens dopamine repeatedly andeliminates the acetylcholine satiety response. Neuroscience 2006;139(3): 813-20.
19. Bassareo V, Di Chiara G. Differential responsiveness of dopaminetransmission to food-stimuli in nucleus accumbens shell/corecompartments. Neuroscience 1999; 89(3): 637-41.
20. Bello NT, Sweigart KL, Lakoski JM, Norgren R, Hajnal A. Restricted feeding with scheduled sucrose access results in anupregulation of the rat dopamine transporter. Am J Physiol RegulIntegr Comp Physiol 2003; 284(5): R1260-8.
21. Hajnal A, Norgren R. Repeated access to sucrose augmentsdopamine turnover in the nucleus accumbens. Neuroreport 2002;13(17): 2213-6.
22. Colantuoni C, Schwenker J, McCarthy J, et al. Excessive sugarintake alters binding to dopamine and mu-opioid receptors in thebrain. Neuroreport 2001; 12(16): 3549-52.
23. Spangler R, Wittkowski KM, Goddard NL, Avena NM, Hoebel BG, Leibowitz SF. Opiate-like effects of sugar on gene expressionin reward areas of the rat brain. Mol Brain Res 2004; 124(2): 134-42.
24. Avena NM, Rada P, Hoebel BG. Underweight rats have enhanceddopamine release and blunted acetylcholine response in the nucleusaccumbens while bingeing on sucrose. Neuroscience 2008; 156(4):865-71.
25. Liang NC, Hajnal A, Norgren R. Sham feeding corn oil increasesaccumbens dopamine in the rat. Am J Physiol Regul Integr CompPhysiol 2006; 291(5): R1236-9.
26. Jimerson DC, Lesem MD, Kaye WH, Brewerton TD. Lowserotonin and dopamine metabolite concentrations in cerebrospinalfluid from bulimic patients with frequent binge episodes. Arch GenPsychiatry 1992 Feb; 49(2): 132-8.
27. Tauscher J, Pirker W, Willeit M, et al. [123I] [beta]-CIT and singlephoton emission computed tomography reveal reduced brainserotonin transporter availability in bulimia nervosa. BiolPsychiatry 2001; 49(4): 326-32.
28. Broft A, Shingleton R, Kaufman J, et al. Striatal dopamine andbulimia nervosa. submitted.
29. Wang GJ, Volkow ND, Logan J, et al. Brain dopamine and obesity. Lancet 2001; 357(9253): 354-7.
30. Corwin RL, Wojnicki FH. Baclofen, raclopride, and naltrexonedifferentially affect intake of fat and sucrose under limited accessconditions. Behav Pharmacol 2009; 20(5-6): 537-48.
31. Wong KJ, Wojnicki FHW, Corwin RLW. Baclofen, raclopride, andnaltrexone differentially affect intake of fat/sucrose mixtures underlimited access conditions. Pharmacol Biochem Behav 2009; 92(3):528-36.
32. Horne RL, Ferguson JM, Pope HG, et al. Treatment of bulimiawith bupropion: a multicenter controlled trial. J Clin Psychiatry 1988; 49(7): 262-6.
33. Yanovski SZ. Binge eating disorder and obesity in 2003: Couldtreating an eating disorder have a positive effect on the obesityepidemic? Int J Eat Disord 2003; 34(S1): S117-S20.
34. Cooper SJ. Effects of opiate agonists and antagonists on fluidintake and saccharin choice in the rat. Neuropharmacology 1983;22(3): 323-8.
35. Carr KD, Simon EJ. Potentiation of reward by hunger is opioidmediated. Brain Res 1984; 297(2): 369-73.
36. Giraudo SQ, Grace MK, Welch CC, Billington CJ, Levine AS. Naloxone's anorectic effect is dependent upon the relativepalatability of food. Pharmacol Biochem Behav 1993; 46(4): 917-21.
37. Johnson PI, Stellar JR, Paul AD. Regional reward differenceswithin the ventral pallidum are revealed by microinjections of a muopiate receptor agonist. Neuropharmacology 1993; 32(12): 1305-14.
38. Weldon DT, O'Hare E, Cleary J, Billington CJ, Levine AS. Effectof naloxone on intake of cornstarch, sucrose, and polycose diets inrestricted and nonrestricted rats. Am J Physiol 1996; 270(6 Pt 2):R1183-8.
39. Drewnowski A, Krahn DD, Demitrack MA, Nairn K, Gosnell BA. Taste responses and preferences for sweet high-fat foods: evidencefor opioid involvement. Physiol Behav 1992; 51(2): 371-9.
40. Yeomans MR, Gray RW. Selective effects of naltrexone on foodpleasantness and intake. Physiol Behav 1996; 60(2): 439-46.
41. Yeomans MR, Gray RW. Effects of naltrexone on food intake andchanges in subjective appetite during eating: evidence for opioidinvolvement in the appetizer effect. Physiol Behav 1997; 62(1): 15-21.
42. Zhang M, Balmadrid C, Kelley AE. Nucleus accumbens opioid,GABAergic, and dopaminergic modulation of palatable foodmotivation: contrasting effects revealed by a progressive ratio studyin the rat. Behav Neurosci 2003; 117(2): 202-11.
43. Kelley AE, Will MJ, Steininger TL, Zhang M, Haber SN. Restricted daily consumption of a highly palatable food (chocolateEnsure(R)) alters striatal enkephalin gene expression. Eur JNeurosci 2003; 18(9): 2592-8.
44. Kelley AE, Bakshi VP, Haber SN, Steininger TL, Will MJ, Zhang M. Opioid modulation of taste hedonics within the ventral striatum. Physiol Behav 2002; 76(3): 365-77.
45. Colantuoni C, Rada P, McCarthy J, et al. Evidence thatintermittent, excessive sugar intake causes endogenous opioiddependence. Obes Res 2002; 10(6): 478-88.
46. Mercer ME, Holder MD. Food cravings, endogenous opioidpeptides, and food intake: a review. Appetite 1997; 29(3): 325-52.
47. Hagan MM, Moss DE. An animal model of bulimia nervosa: opioidsensitivity to fasting episodes. Pharmacol Biochem Behav 1991;39(2): 421-2.
48. Boggiano MM, Chandler PC, Viana JB, Oswald KD, Maldonado CR, Wauford PK. Combined dieting and stress evoke exaggeratedresponses to opioids in binge-eating rats. Behav Neurosci 2005;119(5): 1207-14.
49. Avena NM, Bocarsly ME, Rada P, Kim A, Hoebel BG. After dailybingeing on a sucrose solution, food deprivation induces anxietyand accumbens dopamine/acetylcholine imbalance. Physiol Behav 2008; 94(3): 309-15.
50. Avena NM, Rada P, Hoebel BG. Evidence for sugar addiction:Behavioral and neurochemical effects of intermittent, excessivesugar intake. Neurosci Biobehav Rev 2008; 32(1): 20-39.
51. Davis C, Zai C, Levitan RD, et al. Opiates, overeating and obesity:a psychogenetic analysis. Int J Obes (Lond) 2011 Jan 25.
52. Bencherif B, Guarda AS, Colantuoni C, Ravert HT, Dannals RF, Frost JJ. Regional mu-opioid receptor binding in insular cortex isdecreased in bulimia nervosa and correlates inversely with fastingbehavior. J Nucl Med 2005; 46(8): 1349-51.
53. Naleid AM, Grace MK, Chimukangara M, Billington CJ, Levine AS. Paraventricular opioids alter intake of high-fat but not highsucrosediet depending on diet preference in a binge model offeeding. Am J Physiol Regul Integr Comp Physiol 2007; 293(1):R99-105.
54. Rao RE, Wojnicki FH, Coupland J, Ghosh S, Corwin RL. Baclofen,raclopride, and naltrexone differentially reduce solid fatemulsion intake under limited access conditions. Pharmacol BiochemBehav 2008; 89(4): 581-90.
55. Barbano MF, Le Soux M, Cador M. Involvement of dopamine andopioids in the motivation to eat: influence of palatability, homeostaticstate, and behavioral paradigms. Psychopharmacology (Berl) 2009; 203(3): 475-87.
56. Cottone P, Sabino V, Steardo L, Zorrilla EP. Opioid-dependentanticipatory negative contrast and binge-like eating in rats withlimited access to highly preferred food. Neuropsychopharmacology 2008; 33(3): 524-35.
57. Nathan PJ, Bullmore ET. From taste hedonics to motivationaldrive: central mu-opioid receptors and binge-eating behaviour. Int JNeuropsychopharmacol 2009; 12: 1-14.
58. Krahn DD, Kurth CL, Gomberg E, Drewnowski A. Pathologicaldieting and alcohol use in college women--a continuum ofbehaviors. Eat Behav 2005; 6(1): 43-52.
59. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexonein the treatment of alcohol dependence. Arch Gen Psychiatry 1992;49(11): 876-80.
60. Marrazzi MA, Bacon JP, Kinzie J, Luby ED. Naltrexone use in thetreatment of anorexia nervosa and bulimia nervosa. Int ClinPsychopharmacol 1995; 10(3): 163-72.
61. Alger SA, Schwalberg MD, Bigaouette JM, Michalek AV, Howard LJ. Effect of a tricyclic antidepressant and opiate antagonist onbinge-eating behavior in normoweight bulimic and obese, bingeeatingsubjects. Am J Clin Nutr 1991; 53(4): 865-71.
62. Meyer F. Alleviation of both binge eating and sexual dysfunctionwith naltrexone. J Clin Psychopharmacol 2008; 28(6): 722-3.
63. Neumeister A, Winkler A, Wober-Bingol C. Addition of naltrexoneto fluoxetine in the treatment of binge eating disorder. AJPsychiatry 1999; 156(5): 797.
64. Jonas JM, Gold MS. Treatment of antidepressant-resistant bulimiawith naltrexone. Int J Psychiatry Med 1986-1987; 16(4): 305-9.
65. Marrazzi MA, Bacon JP, Kinzie J, Luby ED. Naltrexone use in thetreatment of anorexia nervosa and bulimia nervosa. Int ClinPsychopharmacol 1995; 10(3): 163-72.
66. Mitchell JE, Christenson G, Jennings J, et al. A placebo-controlled,double-blind crossover study of naltrexone hydrochloride inoutpatients with normal weight bulimia. J Clin Psychopharmacol 1989; 9(2): 94-7.
67. Jonas JM, Gold MS. The use of opiate antagonists in treatingbulimia: a study of low-dose versus high-dose naltrexone. Psychiatry Res 1998; 24(2): 195-9.
68. Fisler JS, Shimizu H, Bray GA. Brain 3-hydroxybutyrate,glutamate, and GABA in a rat model of dietary obesity. PhysiolBehav 1989; 45: 571-7.
69. Ikemoto S, Panksepp J. Dissociations between appetitive andconsummatory responses by pharmacological manipulations ofreward-relevant brain regions. Behav Neurosci 1996; 110(2): 331-45.
70. Pulman KGT, Somerville EM, Clifton PG. Intra-accumbensbaclofen, but not muscimol, mimics the effects of food withdrawalon feeding behaviour. Pharmacol Biochem Behav 2010; 97(1):156-62.
71. Patel SM, Ebenezer IS. The effects of acute multiple intraperitonealinjections of the GABAB receptor agonist baclofen on food intakein rats. Eur J Pharmacol 2008; 601(1-3): 106-10.
72. Higgs S, Barber DJ. Effects of baclofen on feeding behaviourexamined in the runway. Prog Neuropsychopharmacol BiolPsychiatry 2004; 28(2): 405-8.
73. Sato I, Arima H, Ozaki N, et al. Peripherally administered baclofenreduced food intake and body weight in db/db as well as dietinducedobese mice. FEBS Lett 2007; 581(25): 4857-64.
74. Corwin RL. Bingeing rats: a model of intermittent excessivebehavior? Appetite 2006; 46(1): 11-5.
75. Buda-Levin A, Wojnicki FH, Corwin RL. Baclofen reduces fatintake under binge-type conditions. Physiol Behav 2005; 86(1-2):176-84.
76. Wojnicki FHE, Roberts DCS, Corwin RLW. Effects of baclofen onoperant performance for food pellets and vegetable shortening aftera history of binge-type behavior in non-food deprived rats. Pharmacol Biochem Behav 2006; 84(2): 197-206.
77. Petry NM, Heyman GM. Bidirectional modulation of sweet andbitter taste by chlordiazepoxide and Ro 15-4513: lack of effect withGABA drugs. Physiol Behav 1997; 61(1): 119-26.
78. Berner LA, Bocarsly ME, Hoebel BG, Avena NM. Baclofensuppresses binge eating of pure fat but not a sugar-rich or sweet-fatdiet. Behav Pharmacol 2009; 20(7): 631-4.
79. Broft AI, Spanos A, Corwin RL, et al. Baclofen for binge eating:an open-label trial. Int J Eat Disord 2007; 40(8): 687-91.
80. Cifani C, Polidori C, Melotto S, Ciccocioppo R, Massi M. Apreclinical model of binge eating elicited by yo-yo dieting andstressful exposure to food: effect of sibutramine, fluoxetine,topiramate, and midazolam. Psychopharmacology (Berl) 2009;204(1): 113-25.
81. Hedges DW, Reimherr FW, Hoopes SP, et al. Treatment of bulimianervosa with topiramate in a randomized, double-blind, placebocontrolledtrial, part 2: improvement in psychiatric measures. J ClinPsychiatry 2003; 64(12): 1449-54.
82. Hoopes SP, Reimherr FW, Hedges DW, et al. Treatment of bulimianervosa with topiramate in a randomized, double-blind, placebocontrolledtrial, part 1: improvement in binge and purge measures. JClin Psychiatry 2003; 64(11): 1335-41.
83. Nickel C, Tritt K, Muehlbacher M, et al. Topiramate treatment inbulimia nervosa patients: a randomized, double-blind, placebocontrolledtrial. Int J Eat Disord 2005; 38(4): 295-300.
84. McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in thetreatment of binge eating disorder associated with obesity: arandomized, placebo-controlled trial. AJ Psychiatry 2003; 160(2):255-61.
85. McElroy SL, Hudson JI, Capece JA, Beyers K, Fisher AC, Rosenthal NR. Topiramate for the treatment of binge eatingdisorder associated with obesity: a placebo-controlled study. BiolPsychiatry 2007; 61(9): 1039-48.
86. McElroy SL, Shapira NA, Arnold LM, et al. Topiramate in thelong-term treatment of binge-eating disorder associated withobesity. J Clin Psychiatry 2004; 65(11): 1463-9.
87. Schatzberg A, Cole J, DeBattista C. Manual of ClinicalPsychopharmacology. 4th ed. Washington, D.C.: AmericanPsychiatric Publishing; 2003.
88. Claudino AM, de Oliveira IR, Appolinario JC, et al. Double-blind,randomized, placebo-controlled trial of topiramate plus cognitivebehaviortherapy in binge-eating disorder. J Clin Psychiatry 2007;68(9): 1324-32.
89. Melis M, Gessa GL, Diana M. Different mechanisms fordopaminergic excitation induced by opiates and cannabinoids in therat midbrain. Prog Neuropsychopharmacol Biol Psychiatry 2000;24: 993-1006.
90. Vinklerova J, Novakova J, Sulcova A. Inhibition ofmethamphetamine self-administration in rats by cannabinoidreceptor antagonist AM 251. J Psychopharmacol 2002; 16(2): 139-43.
91. Navarro M, Chowen JA, Carrera MRA, et al. CB1 cannabinoidreceptor antagonist-induced opiate withdrawal in morphinedependentrats. Neuroreport 1998; 9: 3397-402.
92. Navarro M, Carrera MRA, Fratta W, et al. Functional interactionbetween opioid and cannabinoid receptors in drug selfadministration. J Neurosci 2001; 21(14): 5344-50.
93. Brown JE, Kassouny M, Cross JK. Kinetic studies of food intakeand sucrose solution preference by rats treated with low doses ofΔ9-tetrahydrocannabinol. Behav Biol 1977; 20: 104-10.
94. Skelly MJ, Guy EG, Howlett AC, Pratt WE. CB1 receptorsmodulate the intake of a sweetened-fat diet in response to muopioidreceptor stimulation of the nucleus accumbens. PharmacolBiochem Behav 2010; 97: 144-51.
95. Foltin RW, Fischman MW, Byrne MF. Effects of smokedmarijuana on food intake and body weight of humans living in aresidential laboratory. Appetite 1988; 11: 1-14.
96. Gendall KA, Joyce PR, Sullivan PF, Bulik CM. Food cravers:characteristics of those who binge. Int J Eat Disord 1998; 23(4):353-60.
97. Gendall KA, Sullivan PE, Joyce PR, Carter FA, Bulik CM. Thenutrient intake of women with bulimia nervosa. Int J Eat Disord 1997; 21(2): 115-27.
98. Monteleone P, Matias I, Martiadis V, De Petrocellis L, Maj M, DiMarzo V. Blood levels of the endocannabinoid anandamide areincreased in anorexia nervosa and in binge-eating disorder, but notin bulimia nervosa. Neuropsychopharmacology 2005; 30(6): 1216-21.
99. Frieling H, Albrecht H, Jedtberg S, et al. Elevated cannabinoid 1receptor mRNA is linked to eating disorder related behavior andattitudes in females with eating disorders. Psychoneuroendocrinology 2009; 34(4): 620-4.
100. Jarrett MM, Scantlebury J, Parker LA. Effect of delta-9-tetrahydrocannabinol on quinine palatability and AM251 onsucrose and quinine palatability using the taste reactivity test. Physiol Behav 2007; 90: 425-30.
101. McLaughlin PJ, Winston K, Sweezey L, et al. The cannabinoidCB1 antagonists SR 141716A and AM 251 suppress food intakeand food-reinforced behavior in a variety of tasks in rats. BehavPharmacol 2003; 14(8): 583-8.
102. Hildebrandt AL, Kelly-Sullivan DM, Black SC. Antiobesity effectsof chronic cannabinoid CB1 receptor antagonist treatment in dietinducedobese mice. Eur J Pharmacol 2003; 462: 125-32.
103. Chambers AP, Sharkey KA, Koopmans HS. Cannabinoid (CB)1receptor antagonist, AM251, causes a sustained reduction of dailyfood intake in the rat. Physiol Behav 2004; 82: 863-9.
104. South T, Deng C, Huang X-F. AM 251 and [beta]-Funaltrexaminereduce fat intake in a fat-preferring strain of mouse. Behav BrainRes 2007; 181(1): 153-7.
105. Mathes CM, Ferrara M, Rowland NE. Selection of a palatabledietary option is not preferentially reduced by cannabinoid CB1receptor antagonist AM251 in female C57Bl/6J mice. PharmacolBiochem Behav 2009; 94(1): 119-23.
106. Mathes CM, Ferrara M, Rowland NE. Cannabinoid-1 receptorantagonists reduce caloric intake by decreasing palatable dietselection in a novel dessert protocol in female rats. Am J PhysiolRegul Integr Comparat Physiol 2008; 295(1): R67-R75.
107. Foltin RW, Haney M. Effects of the cannabinoid antagonistSR141716 (rimonabant) and d-amphetamine on palatable food andfood pellet intake in non-human primates. Pharmacol BiochemBehav 2007; 86(4): 766-73.
108. Simiand J, Keane M, Keane PE, Soubrie P. SR141716, a CB1cannabinoid receptor antagonist, selectively reduces sweet foodintake in marmoset. Behav Pharmacol 1998; 9: 179-81.
109. Thornton-Jones ZD, Vickers SP, Clifton PG. The cannabinoid CB1receptor antagonist SR141716A reduces appetitive andconsummatory responses for food. Psychopharmacology (Berl) 2004; 179(2): 452-60.
110. Di Marzo V, Matias I. Endocannabinoid control of food intake andenergy balance. Nat Neurosci 2005; 8: 585-589.
111. Berner LA, Avena NM, Hoebel BG. Effects of cannabinoidantagonist, AM 251, on sweet-fat combination binge eating.unpublished data.
112. Carai MAM, Colombo G, Gessa GL. Rimonabant: The firsttherapeutically relevant cannabinoid antagonist. Life Sci 2005;77(19): 2339-50.
113. Padwal RS, Majumdar SR. Drug treatments for obesity: orlistat,sibutramine, and rimonabant. Lancet 2007; 369(9555): 71-7.